Sanofi walks away from $500M deal, leav­ing Rev­o­lu­tion alone in push­ing SHP2/KRAS com­bo

In the four years since Sanofi teamed up with Rev­o­lu­tion Med­i­cines around its SHP2 in­hibitor — fronting a $500 mil­lion deal with $50 mil­lion in cash — the part­ners have moved the drug from pre­clin­i­cal stage in­to Phase II stud­ies, de­liv­er­ing the first glimpse of ev­i­dence that the drug may have a role to play in com­bi­na­tion with KRAS in­hibitors.

But Sanofi won’t be go­ing any fur­ther.

Rev­o­lu­tion Med­i­cines put out word late Wednes­day that Sanofi is pulling out of their SHP2 de­vel­op­ment and com­mer­cial­iza­tion col­lab­o­ra­tion, re­turn­ing to the biotech all glob­al rights to RMC-4630. The plan is to get every­thing back in the first half of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER